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Abstract
Background and purpose: Cost-of-illness studies often describe a single aggregate cost of a disease state.
This approach is less helpful for a condition with a spectrum of outcomes like stroke. The modified Rankin Scale is
the most commonly used outcome measure for stroke. We sought to describe the existing evidence on the costs of
stroke according to individual modified Rankin Scale categories. This may be useful in future cost effectiveness modelling
studies of interventions where cost data have not been collected, but disability outcome is known.
Methods: Systematic review of the published literature, searching electronic databases between 2004 and 2015 using validated
search filters. Results were screened to identify studies presenting costs by individual modified Rankin Scale categories.
Results: Of 17,782 unique identified articles, 13 matched all inclusion criteria. In only four of these studies were costs
reported by modified Rankin Scale categories. Most studies included direct medical costs only. Societal costs were
assessed in two studies. Overall, studies had a high methodological and reporting quality. The heterogeneity in costing
methods used in the identified studies prevented meaningful comparison of the reported cost data. Despite this limi-
tation, the costs consistently increased with greater severity (increasing modified Rankin Scale score).
Conclusions: Few cost studies of stroke include information based on stroke recovery measured by individual modified
Rankin Scale categories and the existing data are limited. To reliably capture this information, future studies are needed
that preferably apply standardised costing methods to promote greater potential for use in cost-effectiveness analyses
whereby direct collection of patient-level resource use has not been possible.
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Introduction
Stroke is expensive in terms of its personal, societal and
ﬁnancial impact. The clinical beneﬁt of stroke treat-
ments is usually evaluated according to the functional
outcome measures assessed at least three months after
stroke, when most of the acute recovery has occurred.
The spectrum of stroke outcomes can be assessed using
the mRS,1,2 which is the most prevalent outcome meas-
ure in published trials across recent decades. The 90-
day mRS is also the recommended primary outcome
measure in acute stroke trials by the European Stroke
Organisation (ESO) Outcomes Working Party.1,2
The treatment of stroke is complex and costly with
eﬀective treatments including stroke unit care, intraven-
ous thrombolysis with recombinant tissue plasminogen
activator and most recently, thrombectomy using stent
retriever devices.3,4 Implementation of new treatments
requires the assessment of both cost and outcomes in
relation to alternative available interventions or current
practice using cost-eﬀectiveness analyses. Reliable cost
data relating the mRS by category would be valuable to
the wider stroke community when undertaking these
forms of health economic evaluations.
The collection of robust data for economic evalu-
ations may be complex and time-consuming, increasing
the expense of trials. Therefore, to include cost-
eﬀectiveness evaluations as part of stroke trials can be
challenging, and add to responder burden through the
need for additional questionnaires. Quantifying the
cost of a chronic, disabling condition such as stroke is
complicated since, to provide a full picture of the
cost impact to society, it is important to capture the
direct costs of hospital care, as well as the direct
and indirect costs over the longer term, including
lost productivity. Having reliable estimates of costs
by functional outcome that could be applied in cost-
eﬀectiveness studies would facilitate the ability of inves-
tigators to perform these important evaluations
more often.
We have undertaken a systematic review of the cur-
rent literature investigating the relationship between
costs of stroke and functional outcome as measured
by the mRS as a basis for informing the ﬁeld and
understanding the evidence base that may be available
for cost-eﬀectiveness evaluations where mRS data
have been captured. Through the assessment of the
literature, the ESO aims to eventually develop practical
guidance for the integration of health economic data
collection in future studies. By identifying and
reporting current information on the costs for each
mRS category, these could then be applied in deci-
sion-analytic simulations or estimations of the poten-
tial cost-eﬀectiveness of new interventions in stroke,
where primary collection of cast data has not been
possible.
Methods
We performed a systematic review of the published
literature on studies where the costs of stroke by mRS
category were reported. To guide the systematic review,
we applied the principles of the PRISMA statement
(Appendix 2). We reviewed publications from 1
January 2004 to 13 February 2015 in the following elec-
tronic databases: MEDLINE (Ovid); EMBASE (Ovid);
PsychINFO (EBSCO); CINAHL (EBSCO) and
National Health Service Economic Evaluation
Database (NHS EED).
A sensitive search strategy was designed to incorp-
orate two concepts, (1) Stroke and (2) Health eco-
nomics, which were linked using the Boolean operator
‘AND’. We developed the Concept 1 strategy using
guidance from the Cochrane Stroke Group and the
strategy for Concept 2 using NHS Centre for Review
and Dissemination (CRD) economic study search
guidelines. Terms were tailored to each database
taking into account unique topic headings and syntax.
We also applied a Concept 3 utilising pre-coordination
of information retrieval. This permits direct access to
topic results using Emtree or MeSH subheadings e.g.
Stroke/ec [Economics] for MeSH in Medline and cere-
brovascular accident/dm [Disease Management] for
Emtree in EMBASE. The results of our Concept 1
and Concept 2 searches were linked to Concept 3 by
search operator ‘OR’. Appendix 1 shows the detail of
the search strategies for all databases, and any limita-
tions that applied to the results by author AW.
Duplicate results were ﬁltered out using EndNote
reference manager (version X7.2.1, Thomson Reuters,
USA) and citations were screened by title for relevance.
We also ﬁltered out citations that referred only to con-
ference proceedings or abstracts before screening
citations by title for their relevance.
The following inclusion and exclusion criteria were
applied to title/abstract review of relevant search results:
Inclusion
1. Adult (18þ).
2. Includes costs data (indirect and/or direct costs
reported i.e. hospital stay, carer, medications, loss
of workplace earnings, etc. were all eligible).
3. Acute stroke.
4. mRS reported as the health outcome.
Exclusion
1. Subarachnoid haemorrhage or traumatic brain injury.
2. Protocols or methodologies for randomised con-
trolled trials (RCT).
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3. Cost-eﬀectiveness studies comparing one or more
intervention.
We assessed the included studies for reporting and
methodological quality. Currently, there is no consen-
sus on the best instrument for assessing the methodo-
logical and reporting quality of cost-of-illness studies.
In this review, we followed the recommendation of
Cochrane handbook and utilised the checklist devel-
oped by Drummond and Jeﬀerson,5 as relevant to
cost-of-illness studies This focuses on three domains:
study design; data collection and analysis; and inter-
pretation of results. This checklist can be applied to
range of health economic designs encompassing both
full cost-eﬀectiveness studies and cost-of-illness studies.
The costs from the included studies were abstracted
and then converted to relative 2015 costs in Euros
accounting for inﬂation to allow for direct comparison
of the results. Purchasing power parity (PPP) was used
to calculate the relative value to each currency. Germany
was chosen as having the most representative healthcare
system and economy, and provided the ‘baseline’ Euro
currency from which to calculate the PPP. The calcula-
tions were performed using a web-based calculator
developed by Campbell and the Cochrane Economics
Methods Group in conjunction with the Evidence for
Policy and Practice Information and Coordinating
Centre.6,7
Our aims were to present an estimate of cost of
illness relative to stroke severity as measured by the
mRS. However, given the recognised heterogeneity in
methods used in health economic studies such as cost-
of-illness studies,8 where we were unable to make any
meaningful comparison among studies, we have pre-
sented a narrative review of the ﬁndings.
Results
The literature search yielded 8486 unique full text art-
icles that were screened for inclusion in the study
(Figure 1). From these, we identiﬁed and selected
61 relevant studies for full text review. Of these, only
13 met the inclusion criteria and have been included for
reporting in this review. The characteristics of the
selected studies are shown in Table 1. We included
one study9 that had reported costs by individual
mRS categories as part of a nested cohort study,
whereby these cost-of-illness estimates were then later
applied in a cost-eﬀectiveness analysis of thrombolysis
treatment.
Description of included studies
Among the articles that we identiﬁed, the authors had
investigated populations from diverse locations. Six
studies were European (46%) and two were worldwide
multicentre trials.13,15 Costs were quoted in three cur-
rencies: US dollars, Euros and Pounds Sterling.
A broad range of methods had been used to determine
costs in these currencies, but most had applied PPP to
establish a common value to each currency worldwide.
Patient data collection for the included studies was con-
ducted from March 199815 through December 2011.9
Eleven studies reported costs up to 90 days (84%);
and in ﬁve studies, the longer term costs of stroke of
between 6 to 18 months were reported.11,18–21
Quality assessment
The application of the Drummond et al.5 checklist to
the studies shows the overall quality of the study was
high (Table 4). However, presentation of results in both
aggregate and disaggregate forms was handled poorly
by the authors of these studies. Only 30% presented
results as full ordinal mRS in relation to costs.
Cost of stroke by mRS category
Table 1 shows the total cost of stroke by mRS grade
alongside any measures of uncertainty. The data col-
lected from the studies are heterogeneous, with diverse
resources recorded and included in the overall total cost
per mRS grade (Table 2).
Table 3 shows all mRS scores aggregated with asso-
ciated costs in a common currency (Euro) adjusted
for inﬂation and PPP and presented according to the
time of assessment. The range of costs reported for
mRS 1 is E1614 to E26,079 and for mRS 4: E4,754
to E35,050. The evaluated studies represent a range
of follow-up time points at which the costs were rec-
orded. The majority present costs and mRS scores at
discharge or at 90 days; but some studies only recorded
costs until 10 days or after the initial stroke event
or until hospital discharge. In contrast, the studies of
Fattore et al.18 and Spieler et al.21 focussed on longer
term time points, reporting mean costs for mRS 3
of E5722 and E21,324 over 12 and 18 months,
respectively.
Discussion
The primary aim of this review was to collate the
available data describing the relationship between
costs and outcomes based on the mRS scale categories.
Establishing a reliable estimation of costs by mRS cate-
gories is highly relevant since it may provide an indirect
method for undertaking cost-eﬀectiveness analyses
of novel interventions to be compared against usual
care. This review, however, found that it was not pos-
sible to eﬀectively undertake any meaningful analyses
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due to the heterogeneous nature of the identiﬁed studies
and lack of long-term follow-up data.
We identiﬁed 13 studies incorporating cost of stroke
relating to an mRS score; only three studies provided
an estimate of people who later died from stroke (mRS
6). However, there was signiﬁcant methodological het-
erogeneity which precluded the ability to make any
meaningful comparison between the stated costs
either at a single mRS category or across the scale.
Tables 1 and 2 highlight this heterogeneity, showing
the diversity in time horizon (30–540 days), included
resources and study perspectives.
The time horizon for the collection of costs in these
studies will have a large inﬂuence on the overall costs
associated with stroke. Among the 13 studies identiﬁed,
ﬁve recorded costs up until discharge, ﬁve at 90 days
and ﬁve included costs for longer time frames (6 to 18
months) post stroke. Baeten et al.11 and Hayes et al.19
included costs at multiple time points. Costs in stroke
are highly dependent on the time of collection with the
20256 Citaons idenﬁed in inial search:
   3081  via MEDLINE
   16470 via EMBASE
   125 via CINAHL
   453 via PsycINFO
   127 vis NHS EED
2474 Excluded (duplicate citaons)
17782 Screened for full text 
9296 Excluded (abstract only)
8486 Screened for relevance
13 matching inclusion criteria
211 Reviewed by abstract, tle or both
150 Excluded:
15 – Death only reported outcome
32 – No health economic data
67 – No funconal outcome reported
30 – Paediatric stroke, SAH, TIA
6 – Protocol for stroke
61 Selected for full text review
8275 Excluded (not relevant)
48 Excluded:
28 – Non-mRS funconal outcome
9 – No funconal outcome reported
2 – Modelled costs
7 - mRS not related to health economic 
data
1 – Duplicate study data
1 – Data for mRS not fully presented
4 Idenﬁed from 
reference search
13 included in Review
4 Excluded:
2 – Non-mRS funconal outcome
1 – No funconal outcome
1 – Editorial
Figure 1. Result of systematic search strategy.
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intervention, rehabilitation and associated hospital
costs concentrated in the acute phase (up to 90 days),
while longer term costs including home health care,
social services assistance, as well as productivity loss
are more signiﬁcant across a broader time period.
This is highlighted in the two studies that considered
longer term costs. Fattore et al.18 and Spieler et al.21
provided evidence that direct medical costs were ini-
tially high, but quickly plateaued and remained steady
after the ﬁrst 90 days.21 However, indirect costs such as
productivity losses and paid care increased over time18
highlighting the importance of including of capturing
costs across a broader time horizon when considering
the health economic impact of stroke.
Even when considering the studies that focussed on
collecting data from comparable time horizons, there
remained a high level of variability between costs
reported at each category. This can be accounted for
by the heterogeneity in reported resources (Table 2).
Of the four studies looking at costs at 90 days using
the full ordinal mRS Dawson et al.15 and Christensen
and Morris12 focused on length of stay as their primary
cost metric.22,23 Additionally, Christensen and
Morris11also included coverage of rehabilitation and
home healthcare costs. Hayes et al.19 and Tanny
et al.9 calculated costs related directly from a patient
cohort and extrapolated out of hospital information
from relevant local cost-of-illness studies applied to
their cohort based on discharge destinations.
There was also a high level of heterogeneity in the
reporting of outcomes with only 4 of 13 studies
using the mRS as a complete ordinal scale. In other
studies, the information on costs by mRS was
dichotomised or trichotomised. This latter approach
discards valuable information and undermined the abil-
ity to undertake meaningful comparisons between the
included studies.
To be useful in cost-eﬀectiveness evaluations,
the mRS as a measure of functional ability beyond
the acute phase of the disease needs to be costed
from the perspective of society whereby the direct and
indirect costs to the health sector, patients and other
sectors, e.g. workforce are captured and summarised.
Consistently, the identiﬁed studies provided evidence
Table 2. Perspective and resources collected in identified studies.
Studies Perspective
Index hospitalisation costs Post-acute resources
Thrombolysis
included
in costs
Length
of staya
Direct
medical
costsb
Professional
appointmentsc
Rehabilitation
appointmentsd
Home
health
caree
Productivity
lossf
Length
of stayg
Asil, et al.10 Hospital 3 3 8 patients
in cohort
Baeten11 Healthcare 3 3 3 3 3 Not included
Christensen
and Morris12
Healthcare 3 3 Not included
Christensen et al.13 Healthcare 3 3 Not included
Christensen et al.14 Healthcare 3 3 3 3 3 Not included
Dawson et al.15 Hospital 3 Not included
Dodel et al.16 Hospital 3 3 Included
in cohort
Epifanov et al.17 Hospital 3 3 Not stated
Fattore et al.18 Societal 3 3 3 3 3 3 Not stated
Hayes et al.19 Hospital 3 3 3 3 3 Not stated
Luengo-Fernandez
et al.20
Healthcare 3 3 3 Not stated
Spieler et al.21 Societal 3 3 3 3 3 3 Not stated
Tanny et al.9 Hospital 3 3 3 All patients
in cohort
Note:
aStroke unit, ER, ICU, General ward, intermediate care facility, rehabilitation facility, nursing/convalescence home.
bImaging, diagnostic tests, laboratory tests, surgical interventions and drug costs.
cGeneral practitioner visits, emergency care, outpatient visits.
dPhysiotherapy, speech therapy, ergo therapy.
ePaid home healthcare, informal care, home adaptation, ortheses.
fLoss of working days.
gRehabilitation facility, nursing/convalescence home.
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Table 3. Costs of Stroke by the mRS scores.
Note: Costs displayed in Euro adjusted to 2015 using purchasing power parity with Germany as the target currency. All calculations done using CCEMG –
EPPI-Centre Cost Converter.10, http://eppi.ioe.ac.uk/costconversion/Default.aspx) Table 1 presents costs in original currency at time of study.
Table 4. Quality of Included studies assessed by Dummond et al Checklist.
Note: Colours indicate the level to which the study fulfils criteria; Green – Complete, Yellow – Not clear and Red – Does not fulfil criteria and Blank
cells – Category not appropriate to study.
Wilson et al. 9
that increasing severity of mRS was associated with
increasing direct medical costs. All studies but one15
included direct medical costs such as treatment, diag-
nostic costs and imaging in the estimation of costs at
each mRS category. Hospital stay15 alone was used as
the cost metric in the ﬁnal study and highlighted the
correlation between increased length of stay, mRS
severity and increased costs. Capturing ﬁner grained
direct medical costs in hospitals is important since a
patient who has achieved an mRS of 0 through costly
treatment such as thrombectomy24 will incur little or no
out-of-hospital costs but high direct medical costs. This
review has shown that the estimate of costs includes
some, if not all of the direct medical costs for the
patients care associated with mRS category. However,
to allow for comparison and generic estimates to be
generated, future studies require more consistency in
their methods.
Strengths and limitations
We employed a comprehensive search strategy utilising
validated search strings designed to capture the broad-
est range possible of available literature investigating
both stroke and cost-of-illness studies before combining
these themes. The strategy was employed on the four
major scientiﬁc databases, as well as the NHS EED.
This review was carried out using a deﬁned methodo-
logical approach to data extraction and critical evalu-
ation of included studies.
Our methods still have limitations. The systematic
search and data extraction was carried out by a single
author (AW) under the supervision of TQ. The data col-
lected in the review yielded a highly heterogeneous
sample based on what was available in the published lit-
erature: individual study authors were not approached.
Additionally, the scope of this review was focussed on the
use of the mRS and did not look at the systematic com-
parison of trials investigating the Health economics of
Stroke using alternative outcome measures.
ESO Health economics working group
meeting 2015
The results of the analysis were presented at the 2015
Health economics workshop at the European Stroke
Organisation (ESO) meeting in Glasgow attended by
participants from industry and academia. The atten-
dees agreed in principle that standardisation of health
economic data collected through clinical trials is
required and suggested an international collaboration
to develop guidelines for future trials. Attendees at the
workshop also noted limited comparability across stu-
dies identiﬁed within this review, lending further cre-
dence to the suggestion that standardisation of
resources collected by trialists is required to reduce het-
erogeneity. The importance of including out-of-hospital
direct and indirect costs alongside direct medical costs
that are incurred in hospital in future studies was
emphasised by workshop members due to the long-
term disabling nature of stroke. Attendees also noted
that the WHO Research Agenda for Health Economic
Evaluation (RAHEE) project in Stroke is working
towards similar aims and could be approached for
collaboration.25
Working groups to develop these guidelines have
been assembled and the development of a prospective
study investigating resource use in stroke trials is being
undertaken.
Summary of suggested guidelines for future trials
The result of the systematic review has yielded a four-
point list of suggested guidelines for stroke researchers
to optimise the collection of health economic informa-
tion in future trials which are summarised below.
1. Resource use and mRS to be collected at 90 days
post stroke*.
2. mRS to be presented as a complete ordinal scale to
preserve information relating to costs including
those for patients who later died (mRS 6)*.
3. Collection of resources used to be standardised.
To this end, it is proposed that a group such as the
ESO Economics Working Group develop a template
and recommended costing methods as a resource to
support this activity.
4. Presentation of cost analyses to include measures of
variability allowing for meta-analysis of aggregate
data.
*As recommended by the European Stroke
Organisation (ESO) Outcomes Working Party.
Conclusion
Our ﬁndings have provided a valuable insight into the
heterogeneity seen in health economic reporting in the
ﬁeld of stroke, in particular for the most commonly
collected stroke outcome measure used in trials, the
mRS. This heterogeneity undermined the meaningful
comparison of the included studies and until further
data are available for systematic analysis, we recom-
mend readers refer to the original source data when
assessing critical quality and relevance to ongoing
research. It has also outlined a need for more real
world and trial data investigating health economic out-
comes in stroke looking at both short and long-term
costs related to the mRS as an ordinal scale. This work
has provided a foundation from which to address the
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need for the development of guidelines for health eco-
nomic data and promotion of its importance amongst
current and future trialists in the area of stroke.
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